Total amount: € 0,00
HOW TO ORDER
MINERVA UROLOGICA E NEFROLOGICA
A Journal on Nephrology and Urology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536
Minerva Urologica e Nefrologica 1999 December;51(4):191-5
Treatment of benign prostatic hyperplasia with transurethral electrovaporization of the prostate (TUVP) using Vaportrode VE-B. Two years follow-up
Diana M., Schettini M., Gallucci M.
From the Department of Urology “Cristo Re” Hospital - Rome
Background. The authors report their experience on transurethral vaporization of the prostate with Vaportode for the treatment of BPH.
Methods. In January 1996 we treated 24 patients suffering from cervico-urethral obstruction caused by BPH with electrovaporization of the prostate using a cutting current of between 180 and 250 Watts (average 200 Watts). Exclusion criteria was: PSA>3 ng/ml. The catheter was removed after 24 hours. Follow-up of all patients is 27 months. Twenty-three patients were evaluated.
Results. Results at follow-up were; mean maximum flow (Qmax) 9.31 ml/sec preoperative was 19.5 ml/sec after 6 months, 18.3 after 12 months and 18.0 after 24 months; mean symptom score decreased from 18.1 to 10.4 after 6 months, to 3.2 after 12 months and to 4.8 after 24 months; QL index decreased from 4.6 to 2.3 at 6 months, to 1.4 after 12 months and 24 months; the average avoiding pressure decreased from 62.8 cm/H2O to 23.2 cm/H2O after 6 months, to 21.2 after 12 months and to 23.8 after 24 months. There was no post voiding residual urine 2 days after treatment in all patients.
Conclusions. Follow-up shows transurethral electrovaporization of the prostate is an efficient and safe technique for treatment of BPH.